Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC Reaffirms FY 2013 Guidance-Conference Call


Thursday, 1 Aug 2013 07:00am EDT 

AstraZeneca PLC announced that revenue outlook for fiscal 2013 is unchanged and continue to anticipate a mid to high single-digit decline in revenue on a constant currency basis and core EPS to decline at a rate that is significantly higher than the revenue decline. The Company reported revenue of $27.973 billion and EPS of $6.41 in fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $26.094 billion and EPS of $5.27 for fiscal 2013. 

Company Quote

69.01
1.23 +1.81%
24 Apr 2014